Manufacturing


  • Image attribution tooltip
    Courtesy of Merck KGaA

    German Merck buys manufacturer of key component in mRNA medicines

    Merck KGaA is buying Indianapolis-based Exelead, a specialist in the lipid nanoparticles used to ferry mRNA into the body, for $780 million in cash. 

    By Jan. 6, 2022
  • Image attribution tooltip
    Jeenah Moon via Getty Images

    Pfizer opens gene therapy plant in $800M North Carolina expansion

    The new facility cost nearly $70 million to build, and is part of a major push by the pharma giant to become a leader in genetic medicine manufacturing.

    By Kristin Jensen • Dec. 16, 2021
  • Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Moderna cuts vaccine sales, delivery targets for 2021

    The biotech now expects to deliver between 700 million and 800 million doses this year, down from a previous forecast of 800 million to 1 billion.

    By Nov. 4, 2021
  • Image attribution tooltip
    Courtesy of Merck & Co.

    Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

    Anticipating regulatory clearance of the pill, the group aims to speed access by investing in the manufacturing of generic versions of the drug.

    By Kristin Jensen • Oct. 20, 2021
  • Image attribution tooltip
    Permission granted by Vetter Pharma
    Sponsored by Vetter Pharma

    Emerging therapeutic oligonucleotides – analytical challenges accepted

    A relatively new class of parenteral drug products on the market - therapeutic oligonucleotides – poses new challenges to the pharmaceutical manufacturing process.

    By Alexandra H. Heussner, Ph. D., Laboratory Manager ASL, and Melanie Zerulla-Wernitz, Ph. D., Head of ASL, Development Service, Vetter Pharma-Fertigung GmbH & Co. KG • Oct. 18, 2021
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Under pressure to share technology, Moderna to build vaccine factory in Africa

    The biotech company expects to make its coronavirus vaccine and mRNA shots for other diseases at the planned plant, into which it will invest $500 million.

    By Kristin Jensen • Oct. 7, 2021
  • Image attribution tooltip
    Courtesy of Eli Lilly

    US stocks up on COVID-19 antibody drugs amid shortage concerns

    Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months.

    By Sept. 15, 2021
  • Image attribution tooltip
    Courtesy of CureVac

    CureVac scales back mRNA manufacturing for coronavirus vaccine

    The German biotech, which announced disappointing results for its shot in June, said the move was done in response to reduced demand. 

    By Updated Sept. 15, 2021
  • Image attribution tooltip
    Courtesy of National Resilience; Business Wire

    Moderna expands mRNA vaccine supply in deal with new biotech producer

    The company has previously said it could make up to 3 billion vaccine doses in 2022, depending on how booster shots are authorized.

    By Sept. 8, 2021
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant

    While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.

    By Aug. 10, 2021
  • Image attribution tooltip
    Amgen Inc.

    Amgen, expecting higher demand for its medicines, to build plant in North Carolina

    The biotech is also constructing a new factory in Ohio and, between the two, expects to investment nearly $1 billion over the next few years.

    By Kristin Jensen • Aug. 4, 2021
  • Image attribution tooltip
    Permission granted by Albert Haught

    A pharma merger's impact ripples across West Virginia as Viatris plant closes

    One of the country's oldest and largest drug manufacturing plants shut down Saturday, a consequence of the 2019 merger between Mylan and Pfizer's Upjohn unit. The impact will be felt by a West Virginia city for years to come.

    By July 30, 2021
  • Bluebird preps for split by selling manufacturing plant to well-funded startup

    The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.

    By Kristin Jensen • July 29, 2021
  • Image attribution tooltip
    Sean Gallup via Getty Images

    BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

    Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent. 

    By July 26, 2021
  • Image attribution tooltip
    Permission granted by ZS
    Sponsored by ZS

    Trends shaping biopharma's role in the healthcare ecosystem

    Four trends are shaping the healthcare ecosystem. These present new opportunities for biopharma.

    By Pratap Khedkar and Jude Konzelmann • July 26, 2021
  • Image attribution tooltip
    Permission granted by Faze Medicines / Marissa Fiorucci.
    Sponsored by Avid Bioservices

    Unique commercial experience primes Avid Bioservices for growth

    Discover the bioservices and manufacturing efforts that have made an impact within the biological manufacturing field.

    By Nick Green, Chief Executive Officer, Avid Bioservices • June 28, 2021
  • Image attribution tooltip
    Permission granted by Emergent Biosolutions
    Sponsored by Emergent Biosolutions

    Lyophilized products are on the rise: Here's what you need to know

    To extend the shelf life and improve stability of biopharmaceuticals, a freeze-drying process—and a partner—can help.

    By Kate Silver • June 14, 2021
  • UK drug contractor to be sold to private equity firm in $1.4B deal

    Through a subsidiary, The Carlyle Group will pay a 27% premium to acquire Vectura, a CDMO that specializes in inhaled medicines.

    By Kristin Jensen • May 26, 2021
  • Image attribution tooltip
    Tasos Katopodis via Getty Images

    Emergent CEO defends company from criticism of error that ruined vaccine doses

    The company expects to respond within days to a long list of findings FDA officials made in an inspection of Emergent's Baltimore plant earlier this month.

    By April 30, 2021
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna plans to triple coronavirus vaccine production next year

    The biotech aims to double capacity at plants in Switzerland and Spain, and by 50% at U.S. sites. The total number, however, will depend on the mix of primary and booster doses.

    By April 29, 2021
  • Image attribution tooltip
    Justin Sullivan via Getty Images

    Gilead, Merck to help India access COVID-19 drugs as country's crisis deepens

    Gilead will donate at least 450,000 vials of Veklury, while Merck licensed its experimental antiviral molnupiravir to five generic drugmakers in India. 

    By April 27, 2021
  • Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Sanofi to aid Moderna on final steps in manufacturing coronavirus vaccine

    The French pharma has agreed to "fill and finish" up to 200 million vials of Moderna's shot at its New Jersey plant, the third such manufacturing deal it struck with other vaccine developers. 

    By April 26, 2021
  • Image attribution tooltip
    Tasos Katopodis via Getty Images

    FDA cites Emergent for failings at plant that contaminated J&J doses

    A recent nine-day inspection by agency officials found numerous breaches of manufacturing standards and inadequate training for factory employees. 

    By April 22, 2021
  • Image attribution tooltip
    Permission granted by Johnson & Johnson

    J&J to oversee vaccine production at Emergent factory that ruined doses

    The change, which follows the contractor's costly manufacturing mix-up, will displace production of AstraZeneca's unauthorized shot at the Baltimore site.

    By April 5, 2021
  • Image attribution tooltip
    Permission granted by Johnson & Johnson

    Manufacturing mix-up could blunt supply boost from J&J vaccine

    One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses. 

    By April 1, 2021